407
Participants
Start Date
November 5, 2019
Primary Completion Date
May 3, 2021
Study Completion Date
May 3, 2021
V114
15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
Prevnar 13™
13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
PNEUMOVAX™23
23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
Perinatal HIV Research Unit ( Site 0042), Johannesburg
Wits Reproductive Health and HIV Institute (WRHI) ( Site 0043), Johannesburg
Family Clinic Research With UBUNTU ( Site 0045), Cape Town
Be Part Yoluntu Centre ( Site 0041), Paarl
Chulalongkorn University-Pediatrics ( Site 0062), Bangkok
Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0064), Bangkok
Vinnitsa Reg Cntr for AIDS Prevention-Control-Outpatient clinic dept ( Site 0086), Vinnytsia
Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0063), Amphoe Mueang
Community Instit Dnipropetrovsk Municipal clinical Hospital #21 ( Site 0088), Dnipro
Dnipropetrovsk Regional Center of Socially Significant Diseases ( Site 0082), Dnipro
CM Clinical Trial Unit-CM Clinical Trial Unit ( Site 0061), Chiang Mai
Odesa Regional Center of Socially Significant Diseases ( Site 0083), Odesa
Zaporizhzhya Regional Clinical Children's Hospital ( Site 0089), Zaporizhzhya
Merck Sharp & Dohme LLC
INDUSTRY